Concepts (240)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Stroke | 8 | 2023 | 256 | 1.320 |
Why?
|
| Clinical Competence | 11 | 2020 | 234 | 0.840 |
Why?
|
| Clinical Decision-Making | 2 | 2021 | 63 | 0.830 |
Why?
|
| Emergency Service, Hospital | 1 | 2021 | 121 | 0.640 |
Why?
|
| Brain Ischemia | 6 | 2020 | 87 | 0.640 |
Why?
|
| Education, Medical | 3 | 2011 | 68 | 0.570 |
Why?
|
| Drug Monitoring | 1 | 2017 | 36 | 0.540 |
Why?
|
| Vancomycin | 1 | 2017 | 58 | 0.530 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2021 | 834 | 0.530 |
Why?
|
| Guideline Adherence | 1 | 2017 | 95 | 0.520 |
Why?
|
| Staphylococcal Infections | 1 | 2017 | 87 | 0.500 |
Why?
|
| Emergency Medical Technicians | 6 | 2006 | 10 | 0.490 |
Why?
|
| Emergency Medical Services | 6 | 2005 | 81 | 0.480 |
Why?
|
| Brain | 1 | 2021 | 753 | 0.470 |
Why?
|
| Emergency Treatment | 3 | 2005 | 26 | 0.420 |
Why?
|
| Anti-Bacterial Agents | 1 | 2017 | 534 | 0.400 |
Why?
|
| Professional Role | 2 | 2020 | 46 | 0.380 |
Why?
|
| Humans | 42 | 2023 | 28585 | 0.370 |
Why?
|
| Internationality | 1 | 2011 | 31 | 0.340 |
Why?
|
| Computer Simulation | 5 | 2005 | 231 | 0.330 |
Why?
|
| Physicians | 1 | 2011 | 83 | 0.320 |
Why?
|
| Health Occupations | 2 | 2020 | 9 | 0.320 |
Why?
|
| Aged, 80 and over | 10 | 2021 | 2045 | 0.310 |
Why?
|
| Neurology | 3 | 2005 | 10 | 0.310 |
Why?
|
| Thrombolytic Therapy | 4 | 2021 | 39 | 0.280 |
Why?
|
| Aged | 13 | 2023 | 5525 | 0.270 |
Why?
|
| Problem-Based Learning | 3 | 2019 | 62 | 0.270 |
Why?
|
| Retrospective Studies | 7 | 2022 | 2612 | 0.240 |
Why?
|
| Middle Aged | 14 | 2021 | 7310 | 0.230 |
Why?
|
| Tissue Plasminogen Activator | 3 | 2021 | 36 | 0.230 |
Why?
|
| Bioterrorism | 1 | 2005 | 28 | 0.220 |
Why?
|
| Infection Control | 1 | 2005 | 33 | 0.220 |
Why?
|
| Male | 18 | 2023 | 13772 | 0.220 |
Why?
|
| Intracranial Aneurysm | 2 | 2017 | 59 | 0.220 |
Why?
|
| Diagnosis, Differential | 2 | 2021 | 378 | 0.210 |
Why?
|
| Nocardia Infections | 1 | 2003 | 4 | 0.200 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2021 | 100 | 0.200 |
Why?
|
| Opportunistic Infections | 1 | 2003 | 17 | 0.200 |
Why?
|
| Pilot Projects | 6 | 2023 | 458 | 0.200 |
Why?
|
| Piperazines | 1 | 2023 | 50 | 0.200 |
Why?
|
| Clinical Clerkship | 1 | 2003 | 20 | 0.200 |
Why?
|
| Pyridines | 1 | 2023 | 108 | 0.190 |
Why?
|
| Lung Diseases | 1 | 2003 | 43 | 0.190 |
Why?
|
| Fibrinolytic Agents | 2 | 2021 | 70 | 0.190 |
Why?
|
| Antineoplastic Agents | 2 | 2021 | 681 | 0.190 |
Why?
|
| Adult | 12 | 2021 | 7922 | 0.190 |
Why?
|
| Treatment Outcome | 5 | 2021 | 2402 | 0.180 |
Why?
|
| Predictive Value of Tests | 2 | 2021 | 480 | 0.180 |
Why?
|
| Female | 16 | 2021 | 15472 | 0.180 |
Why?
|
| Naloxone | 1 | 2021 | 19 | 0.180 |
Why?
|
| Terrorism | 3 | 2006 | 10 | 0.180 |
Why?
|
| Wearable Electronic Devices | 1 | 2021 | 13 | 0.180 |
Why?
|
| Hydrocephalus | 1 | 2022 | 55 | 0.180 |
Why?
|
| Narcotic Antagonists | 1 | 2021 | 32 | 0.180 |
Why?
|
| Infusions, Intravenous | 1 | 2021 | 102 | 0.170 |
Why?
|
| Hyperglycemia | 1 | 2022 | 78 | 0.170 |
Why?
|
| Macaca mulatta | 1 | 2020 | 50 | 0.170 |
Why?
|
| Genome | 1 | 2020 | 56 | 0.170 |
Why?
|
| Bacterial Vaccines | 1 | 2020 | 29 | 0.170 |
Why?
|
| Professional Practice | 1 | 2020 | 9 | 0.160 |
Why?
|
| Thrombectomy | 1 | 2020 | 28 | 0.160 |
Why?
|
| Voluntary Health Agencies | 1 | 2000 | 1 | 0.160 |
Why?
|
| State Health Plans | 1 | 2000 | 3 | 0.160 |
Why?
|
| Myocardial Ischemia | 1 | 2000 | 73 | 0.160 |
Why?
|
| Clostridium Infections | 1 | 2020 | 67 | 0.160 |
Why?
|
| Patient Simulation | 3 | 2005 | 13 | 0.160 |
Why?
|
| Prospective Studies | 6 | 2023 | 1272 | 0.150 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2021 | 135 | 0.150 |
Why?
|
| Health Education | 1 | 2000 | 75 | 0.150 |
Why?
|
| Health Personnel | 1 | 2000 | 96 | 0.150 |
Why?
|
| Brain Infarction | 2 | 2020 | 10 | 0.150 |
Why?
|
| Terminology as Topic | 1 | 2019 | 61 | 0.150 |
Why?
|
| Concept Formation | 1 | 2018 | 7 | 0.140 |
Why?
|
| Thinking | 1 | 2018 | 14 | 0.140 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2020 | 550 | 0.140 |
Why?
|
| Cerebral Hemorrhage | 2 | 2022 | 93 | 0.140 |
Why?
|
| Breast Neoplasms | 1 | 2023 | 472 | 0.140 |
Why?
|
| Program Evaluation | 3 | 2006 | 172 | 0.140 |
Why?
|
| Cohort Studies | 2 | 2017 | 893 | 0.140 |
Why?
|
| Hospitals, Teaching | 1 | 2017 | 26 | 0.140 |
Why?
|
| Australia | 1 | 2017 | 40 | 0.140 |
Why?
|
| Practice Guidelines as Topic | 1 | 2019 | 244 | 0.140 |
Why?
|
| Curriculum | 6 | 2006 | 296 | 0.140 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2020 | 671 | 0.130 |
Why?
|
| Academic Medical Centers | 1 | 2017 | 76 | 0.130 |
Why?
|
| Aneurysm, Ruptured | 1 | 2017 | 17 | 0.130 |
Why?
|
| Fucosyltransferases | 1 | 2016 | 4 | 0.130 |
Why?
|
| Bronchiectasis | 1 | 2016 | 3 | 0.130 |
Why?
|
| Staphylococcus aureus | 1 | 2017 | 121 | 0.130 |
Why?
|
| United States | 4 | 2005 | 2201 | 0.130 |
Why?
|
| Internal Medicine | 2 | 2002 | 28 | 0.120 |
Why?
|
| Inservice Training | 2 | 2006 | 9 | 0.110 |
Why?
|
| Furans | 1 | 2014 | 5 | 0.110 |
Why?
|
| Lignans | 1 | 2014 | 10 | 0.110 |
Why?
|
| Quercetin | 1 | 2014 | 14 | 0.110 |
Why?
|
| Stents | 2 | 2012 | 121 | 0.110 |
Why?
|
| Follow-Up Studies | 1 | 2017 | 1026 | 0.110 |
Why?
|
| Multimedia | 2 | 2005 | 7 | 0.110 |
Why?
|
| Prosthesis-Related Infections | 1 | 2014 | 14 | 0.110 |
Why?
|
| Bioprosthesis | 1 | 2014 | 21 | 0.110 |
Why?
|
| Endocarditis | 1 | 2014 | 20 | 0.110 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2014 | 64 | 0.110 |
Why?
|
| Internship and Residency | 3 | 2005 | 250 | 0.110 |
Why?
|
| Platelet Count | 1 | 2014 | 111 | 0.100 |
Why?
|
| Program Development | 2 | 2006 | 85 | 0.100 |
Why?
|
| Blood Coagulation | 1 | 2014 | 120 | 0.100 |
Why?
|
| Mechanical Thrombolysis | 1 | 2012 | 3 | 0.090 |
Why?
|
| Neoplasms | 1 | 2021 | 857 | 0.090 |
Why?
|
| Students, Medical | 3 | 2005 | 102 | 0.090 |
Why?
|
| Blood Platelets | 1 | 2014 | 206 | 0.090 |
Why?
|
| Endovascular Procedures | 1 | 2012 | 71 | 0.090 |
Why?
|
| Prostatic Neoplasms | 1 | 2014 | 282 | 0.090 |
Why?
|
| Educational Measurement | 3 | 2019 | 131 | 0.090 |
Why?
|
| Florida | 7 | 2006 | 55 | 0.090 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2016 | 478 | 0.090 |
Why?
|
| Cell Proliferation | 1 | 2014 | 817 | 0.090 |
Why?
|
| Coronary Artery Bypass | 1 | 2012 | 68 | 0.090 |
Why?
|
| Health Services Needs and Demand | 1 | 2011 | 37 | 0.090 |
Why?
|
| Young Adult | 4 | 2021 | 2804 | 0.080 |
Why?
|
| Cerebral Angiography | 3 | 2017 | 38 | 0.080 |
Why?
|
| Global Health | 1 | 2011 | 54 | 0.080 |
Why?
|
| Time Factors | 3 | 2020 | 1600 | 0.080 |
Why?
|
| Biomarkers | 2 | 2023 | 770 | 0.080 |
Why?
|
| Personnel Management | 1 | 1988 | 4 | 0.070 |
Why?
|
| Personnel Selection | 1 | 1988 | 11 | 0.070 |
Why?
|
| Adolescent | 4 | 2021 | 3165 | 0.060 |
Why?
|
| Disaster Planning | 1 | 2006 | 24 | 0.060 |
Why?
|
| Interviews as Topic | 2 | 2021 | 160 | 0.060 |
Why?
|
| Protective Clothing | 1 | 2005 | 4 | 0.060 |
Why?
|
| Toxins, Biological | 1 | 2005 | 7 | 0.060 |
Why?
|
| Decontamination | 1 | 2005 | 8 | 0.060 |
Why?
|
| Virus Diseases | 1 | 2005 | 39 | 0.060 |
Why?
|
| Cross-Sectional Studies | 2 | 2021 | 988 | 0.050 |
Why?
|
| Bacterial Infections | 1 | 2005 | 56 | 0.050 |
Why?
|
| Cardiology | 2 | 2002 | 48 | 0.050 |
Why?
|
| Anesthesiology | 2 | 2001 | 19 | 0.050 |
Why?
|
| Education, Continuing | 2 | 2001 | 11 | 0.050 |
Why?
|
| Plasminogen Activators | 2 | 2000 | 7 | 0.050 |
Why?
|
| Receptor, ErbB-2 | 1 | 2023 | 33 | 0.050 |
Why?
|
| Alanine | 1 | 2023 | 40 | 0.050 |
Why?
|
| Child | 2 | 2021 | 2271 | 0.050 |
Why?
|
| Blood Volume | 1 | 2022 | 8 | 0.050 |
Why?
|
| Sphingolipids | 1 | 2022 | 20 | 0.050 |
Why?
|
| Competitive Behavior | 1 | 2001 | 17 | 0.050 |
Why?
|
| Longitudinal Studies | 1 | 2023 | 426 | 0.050 |
Why?
|
| Task Performance and Analysis | 1 | 2001 | 43 | 0.050 |
Why?
|
| Philadelphia | 1 | 2021 | 2 | 0.040 |
Why?
|
| Patient Care Team | 1 | 2001 | 66 | 0.040 |
Why?
|
| Amino Acids | 1 | 2022 | 85 | 0.040 |
Why?
|
| Molecular Sequence Annotation | 1 | 2020 | 21 | 0.040 |
Why?
|
| Whole Genome Sequencing | 1 | 2020 | 23 | 0.040 |
Why?
|
| Metabolomics | 1 | 2022 | 87 | 0.040 |
Why?
|
| Emergency Medical Service Communication Systems | 1 | 2000 | 1 | 0.040 |
Why?
|
| Education, Medical, Graduate | 1 | 2001 | 117 | 0.040 |
Why?
|
| Prognosis | 1 | 2003 | 807 | 0.040 |
Why?
|
| Bone Marrow | 1 | 2021 | 81 | 0.040 |
Why?
|
| Immunization Schedule | 1 | 2020 | 13 | 0.040 |
Why?
|
| Skilled Nursing Facilities | 1 | 2020 | 3 | 0.040 |
Why?
|
| Feces | 1 | 2021 | 114 | 0.040 |
Why?
|
| Hospices | 1 | 2020 | 7 | 0.040 |
Why?
|
| Long-Term Care | 1 | 2020 | 32 | 0.040 |
Why?
|
| Mississippi | 1 | 2000 | 5 | 0.040 |
Why?
|
| Disability Evaluation | 1 | 2020 | 54 | 0.040 |
Why?
|
| Organizational Objectives | 1 | 2000 | 16 | 0.040 |
Why?
|
| Patient Advocacy | 1 | 2000 | 16 | 0.040 |
Why?
|
| Propensity Score | 1 | 2020 | 59 | 0.040 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2021 | 327 | 0.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2023 | 414 | 0.040 |
Why?
|
| DNA, Bacterial | 1 | 2021 | 309 | 0.040 |
Why?
|
| Teaching Materials | 1 | 1999 | 6 | 0.040 |
Why?
|
| Educational Technology | 1 | 1999 | 6 | 0.040 |
Why?
|
| Quality of Life | 1 | 2023 | 504 | 0.040 |
Why?
|
| Recovery of Function | 1 | 2020 | 122 | 0.040 |
Why?
|
| Patient Discharge | 1 | 2020 | 108 | 0.040 |
Why?
|
| Genetic Variation | 1 | 2020 | 245 | 0.040 |
Why?
|
| Hospital Mortality | 1 | 2020 | 157 | 0.040 |
Why?
|
| Age Factors | 1 | 2020 | 734 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2020 | 622 | 0.030 |
Why?
|
| Myocardial Infarction | 1 | 2000 | 351 | 0.030 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2017 | 28 | 0.030 |
Why?
|
| Qualitative Research | 1 | 2018 | 200 | 0.030 |
Why?
|
| Sputum | 1 | 2016 | 8 | 0.030 |
Why?
|
| Minority Groups | 1 | 2017 | 75 | 0.030 |
Why?
|
| Respiratory Function Tests | 1 | 2016 | 27 | 0.030 |
Why?
|
| Urban Population | 1 | 2017 | 86 | 0.030 |
Why?
|
| Poverty | 1 | 2017 | 89 | 0.030 |
Why?
|
| Pseudomonas Infections | 1 | 2016 | 25 | 0.030 |
Why?
|
| Bronchoscopy | 1 | 2016 | 35 | 0.030 |
Why?
|
| Biopsy | 1 | 2016 | 207 | 0.030 |
Why?
|
| Prevalence | 1 | 2017 | 510 | 0.030 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2016 | 72 | 0.030 |
Why?
|
| Schools, Medical | 2 | 2002 | 46 | 0.030 |
Why?
|
| Genotype | 1 | 2016 | 461 | 0.030 |
Why?
|
| Ischemic Attack, Transient | 1 | 1995 | 26 | 0.030 |
Why?
|
| Receptors, Androgen | 1 | 2014 | 26 | 0.030 |
Why?
|
| Microbiota | 1 | 2016 | 98 | 0.030 |
Why?
|
| Cerebrovascular Disorders | 1 | 1995 | 46 | 0.030 |
Why?
|
| Risk Factors | 1 | 2020 | 2111 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2014 | 104 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2016 | 461 | 0.030 |
Why?
|
| Androgens | 1 | 2014 | 47 | 0.030 |
Why?
|
| Mortality | 1 | 2014 | 46 | 0.030 |
Why?
|
| Disease Progression | 1 | 2016 | 475 | 0.030 |
Why?
|
| STAT3 Transcription Factor | 1 | 2014 | 97 | 0.030 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2014 | 135 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2014 | 155 | 0.030 |
Why?
|
| Surveys and Questionnaires | 2 | 2006 | 994 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2014 | 611 | 0.030 |
Why?
|
| Functional Laterality | 1 | 2012 | 64 | 0.020 |
Why?
|
| Reproducibility of Results | 2 | 2005 | 782 | 0.020 |
Why?
|
| Models, Educational | 2 | 2003 | 23 | 0.020 |
Why?
|
| Coronary Angiography | 1 | 2012 | 150 | 0.020 |
Why?
|
| MicroRNAs | 1 | 2014 | 301 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2014 | 1341 | 0.020 |
Why?
|
| Remission, Spontaneous | 1 | 1990 | 8 | 0.020 |
Why?
|
| Neurologic Examination | 1 | 1990 | 22 | 0.020 |
Why?
|
| Chicago | 1 | 1988 | 6 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 1988 | 79 | 0.020 |
Why?
|
| Faculty, Medical | 1 | 1988 | 59 | 0.020 |
Why?
|
| Interpersonal Relations | 1 | 1988 | 65 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2014 | 1455 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2012 | 631 | 0.020 |
Why?
|
| Animals | 1 | 2020 | 10583 | 0.020 |
Why?
|
| Certification | 1 | 2006 | 16 | 0.020 |
Why?
|
| Competency-Based Education | 1 | 2003 | 17 | 0.010 |
Why?
|
| Professional Competence | 1 | 2003 | 37 | 0.010 |
Why?
|
| Universities | 1 | 2003 | 124 | 0.010 |
Why?
|
| Planning Techniques | 1 | 2001 | 7 | 0.010 |
Why?
|
| Organizational Innovation | 1 | 2000 | 20 | 0.010 |
Why?
|
| Physician-Patient Relations | 1 | 2002 | 116 | 0.010 |
Why?
|
| Clinical Protocols | 1 | 2000 | 46 | 0.010 |
Why?
|
| Triage | 1 | 2000 | 34 | 0.010 |
Why?
|
| Physical Examination | 1 | 2000 | 53 | 0.010 |
Why?
|
| General Surgery | 1 | 1999 | 63 | 0.010 |
Why?
|
| Laparoscopy | 1 | 1999 | 156 | 0.010 |
Why?
|
| Embolism | 1 | 1995 | 14 | 0.010 |
Why?
|
| Arteriosclerosis | 1 | 1995 | 30 | 0.010 |
Why?
|
| Hematologic Diseases | 1 | 1995 | 11 | 0.010 |
Why?
|
| Heart Diseases | 1 | 1995 | 71 | 0.010 |
Why?
|
| Vascular Diseases | 1 | 1995 | 68 | 0.010 |
Why?
|